Infectious diseases clinician's variation in the management of pediatric Staphylococcus aureus bacteraemia and equipoise for clinical trials

Anita J. Campbell, Steven Y.C. Tong, Joshua S. Davis, Alasdair P.S. Munro, Christopher C. Blyth, Asha C. Bowen

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Pediatric Staphylococcus aureus bacteraemia is one of the leading causes of community-acquired blood-stream infection in the developed world; however, our understanding of management practices by treating clinicians is limited.

Methods: The authors designed a web-based clinician survey with support from the Australian and New Zealand Pediatric Infectious Diseases group, of the Australasian Society of Infectious Diseases. Clinicians were presented with three pediatric cases of varying severity. Antibiotic choice, durations of intravenous and oral therapy and research priorities for pediatric S. aureus bacteraemia trials were gauged.

Results and Conclusion: Large variation in antibiotic prescribing amongst clinicians is demonstrated and increased, corresponding with escalating case complexity and persisting MRSA bacteraemia. Most clinicians chose defining optimal duration of therapy for S. aureus bacteraemia as their top clinical trial priority. These findings highlight the importance of prioritizing pediatric S. aureus bacteraemia clinical trials, to inform guidelines and best practice management.

Original languageEnglish
Article number249
Pages (from-to)1-4
Number of pages4
JournalFrontiers in Pediatrics
Volume7
Issue numberJune
DOIs
Publication statusPublished - 18 Jun 2019

Fingerprint

Bacteremia
Communicable Diseases
Staphylococcus aureus
Clinical Trials
Pediatrics
Practice Management
Anti-Bacterial Agents
Methicillin-Resistant Staphylococcus aureus
New Zealand
Practice Guidelines
boldenone undecylenate
Guidelines
Therapeutics
Infection
Research

Cite this

@article{698b3b140fb847be8692f9ea92c1481f,
title = "Infectious diseases clinician's variation in the management of pediatric Staphylococcus aureus bacteraemia and equipoise for clinical trials",
abstract = "Background: Pediatric Staphylococcus aureus bacteraemia is one of the leading causes of community-acquired blood-stream infection in the developed world; however, our understanding of management practices by treating clinicians is limited. Methods: The authors designed a web-based clinician survey with support from the Australian and New Zealand Pediatric Infectious Diseases group, of the Australasian Society of Infectious Diseases. Clinicians were presented with three pediatric cases of varying severity. Antibiotic choice, durations of intravenous and oral therapy and research priorities for pediatric S. aureus bacteraemia trials were gauged. Results and Conclusion: Large variation in antibiotic prescribing amongst clinicians is demonstrated and increased, corresponding with escalating case complexity and persisting MRSA bacteraemia. Most clinicians chose defining optimal duration of therapy for S. aureus bacteraemia as their top clinical trial priority. These findings highlight the importance of prioritizing pediatric S. aureus bacteraemia clinical trials, to inform guidelines and best practice management.",
keywords = "Infectious diseases physician, Management, Pediatric, Staphylococcus aureus bacteraemia, Survey",
author = "Campbell, {Anita J.} and Tong, {Steven Y.C.} and Davis, {Joshua S.} and Munro, {Alasdair P.S.} and Blyth, {Christopher C.} and Bowen, {Asha C.}",
year = "2019",
month = "6",
day = "18",
doi = "10.3389/fped.2019.00249",
language = "English",
volume = "7",
pages = "1--4",
journal = "Frontiers in Pediatrics",
issn = "2296-2360",
publisher = "Frontiers Research Foundation",
number = "June",

}

Infectious diseases clinician's variation in the management of pediatric Staphylococcus aureus bacteraemia and equipoise for clinical trials. / Campbell, Anita J.; Tong, Steven Y.C.; Davis, Joshua S.; Munro, Alasdair P.S.; Blyth, Christopher C.; Bowen, Asha C.

In: Frontiers in Pediatrics, Vol. 7, No. June, 249, 18.06.2019, p. 1-4.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Infectious diseases clinician's variation in the management of pediatric Staphylococcus aureus bacteraemia and equipoise for clinical trials

AU - Campbell, Anita J.

AU - Tong, Steven Y.C.

AU - Davis, Joshua S.

AU - Munro, Alasdair P.S.

AU - Blyth, Christopher C.

AU - Bowen, Asha C.

PY - 2019/6/18

Y1 - 2019/6/18

N2 - Background: Pediatric Staphylococcus aureus bacteraemia is one of the leading causes of community-acquired blood-stream infection in the developed world; however, our understanding of management practices by treating clinicians is limited. Methods: The authors designed a web-based clinician survey with support from the Australian and New Zealand Pediatric Infectious Diseases group, of the Australasian Society of Infectious Diseases. Clinicians were presented with three pediatric cases of varying severity. Antibiotic choice, durations of intravenous and oral therapy and research priorities for pediatric S. aureus bacteraemia trials were gauged. Results and Conclusion: Large variation in antibiotic prescribing amongst clinicians is demonstrated and increased, corresponding with escalating case complexity and persisting MRSA bacteraemia. Most clinicians chose defining optimal duration of therapy for S. aureus bacteraemia as their top clinical trial priority. These findings highlight the importance of prioritizing pediatric S. aureus bacteraemia clinical trials, to inform guidelines and best practice management.

AB - Background: Pediatric Staphylococcus aureus bacteraemia is one of the leading causes of community-acquired blood-stream infection in the developed world; however, our understanding of management practices by treating clinicians is limited. Methods: The authors designed a web-based clinician survey with support from the Australian and New Zealand Pediatric Infectious Diseases group, of the Australasian Society of Infectious Diseases. Clinicians were presented with three pediatric cases of varying severity. Antibiotic choice, durations of intravenous and oral therapy and research priorities for pediatric S. aureus bacteraemia trials were gauged. Results and Conclusion: Large variation in antibiotic prescribing amongst clinicians is demonstrated and increased, corresponding with escalating case complexity and persisting MRSA bacteraemia. Most clinicians chose defining optimal duration of therapy for S. aureus bacteraemia as their top clinical trial priority. These findings highlight the importance of prioritizing pediatric S. aureus bacteraemia clinical trials, to inform guidelines and best practice management.

KW - Infectious diseases physician

KW - Management

KW - Pediatric

KW - Staphylococcus aureus bacteraemia

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=85068842017&partnerID=8YFLogxK

U2 - 10.3389/fped.2019.00249

DO - 10.3389/fped.2019.00249

M3 - Article

VL - 7

SP - 1

EP - 4

JO - Frontiers in Pediatrics

JF - Frontiers in Pediatrics

SN - 2296-2360

IS - June

M1 - 249

ER -